EO 14187
Protecting Children From Chemical and Surgical Mutilation
HealthcareGovernment Reform
Ad Space (leaderboard)
Summary
This executive order directs federal agencies to cease funding, supporting, or promoting gender-affirming medical treatments for minors under 19 years old, including puberty blockers, hormone therapy, and surgeries. It requires the Department of Health and Human Services to review literature on gender dysphoria treatment, directs agencies to defund medical institutions providing these treatments, and excludes such care from federal employee and military health insurance programs.
Key Points
- 1Defines 'chemical and surgical mutilation' to include puberty blockers, sex hormones, and surgical procedures related to gender transition in minors under 19 years old
- 2Directs federal agencies to end reliance on World Professional Association for Transgender Health (WPATH) guidance and requires HHS to publish a literature review on gender dysphoria treatment within 90 days
- 3Requires agencies providing research and education grants to medical institutions to ensure recipients cease providing these treatments to children
- 4Instructs HHS to use Medicare/Medicaid regulations and other mechanisms to prevent coverage of these treatments
- 5Directs the Department of Defense to exclude gender-affirming medical treatments from TRICARE military health insurance coverage
This summary is for informational purposes only. It may not capture all nuances of the executive order. Always refer to the official text for authoritative information.
Ad Space (rectangle)